ISRCTN36126048已完成1 期
A clinical trial to determine the safety, tolerability and immunogenicity of the candidate Mycobacterium avium subspecies paratuberculosis (MAP) vaccines ChAdOx2 HAV and MVA HAV in patients with active Crohn’s disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 28
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 18 to 50 years.
- •2. Confirmed diagnosis of Crohn’s disease diagnosed according to standard clinical, endoscopic, radiological or histological criteria.
- •3. Mild to moderately active Crohn’s inflammation as defined by one or more of a raised CRP >10mg/L, faecal calprotectin >150 and a CDAI >150 but <320.
- •4. Active Crohn’s inflammation in at least one segment of ileum or colon on colonoscopy or flexible sigmoidoscopy.
- •5. No immunomodulatory treatment (thiopurines, methotrexate, tacrolimus, anti-TNFalpha antibody therapy, anti-alpha4beta7 antibody therapy, anti-p40 antibody therapy) currently or within the last 3 months.
- •6. Able to comply with all study requirements.
- •7. For females only, willingness to practice continuous effective contraception (see below) during the study and a negative pregnancy test on the day(s) of screening and vaccination.
- •8. Agreement to refrain from blood donation during the course of the study.
- •9. Provide written informed consent.
排除标准
- •Current exclusion criteria as of 18/11/2021:
- •1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period.
- •2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data.
- •3. Prior receipt of an adenoviral vectored vaccine in the last 28 days.
- •4. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- •5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections.
- •6. Any immunosuppressive medication currently or within the preceding 3 months including corticosteroids (except inhaled steroid or topical steroid), thiopurines, methotrexate, tacrolimus and any biological therapy.
- •7. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. Egg allergy)
- •8. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
- •9. Any history of anaphylaxis in relation to vaccination.
- •10. Unable to provide written informed consent.
- •11. Pregnancy, lactation or willingness/intention to become pregnant during the study.
- •12. History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ).
- •13. History of serious psychiatric condition likely to affect participation in the study.
- •14. Bleeding disorder (e.g. Factor deficiency, coagulopathy or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
- •15. Any other serious chronic illness requiring hospital specialist supervision.
- •16. Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week.
- •17. Suspected or known injecting drug abuse in the 5 years preceding enrolment.
- •18. Seropositive for hepatitis C (antibodies to HCV).
- •19. Seropositive for hepatitis B surface antigen (HBsAg).
- •20. Any clinically significant abnormal finding on screening biochemistry or hematology blood tests or urinalysis.
- •21. Any other significant disease, disorder or finding which may significantly increase the risk to the participant
- •Previous exclusion criteria:
- •1. Participation in another research study involving receipt of an investigational product in the 30 days preceding enrolment, or planned use during the study period.
- •2. Prior receipt of an investigational vaccine likely to impact on interpretation of the trial data.
- •3. Prior receipt of an adenoviral vectored vaccine in the last 12 months.
- •4. Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate.
- •5. Any confirmed or suspected immunosuppressive or immunodeficient state, including HIV infection; asplenia; recurrent, severe infections.
- •6. Any immunosuppressive medication currently or within the preceding 3 months including corticosteroids (except inhaled steroid or topical steroid), thiopurines, methotrexate, tacrolimus and any biological therapy.
- •7. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine (e.g. Egg allergy)
- •8. Any history of hereditary angioedema, acquired angioedema, or idiopathic angioedema.
- •9. Any history of anaphylaxis in relation to vaccination.
- •10. Unable to provide written informed consent.
- •11. Pregnancy, lactation or
研究者
相似试验
招募中
1 期
SHED for cerebral palsyCerebral PalsyJPRN-jRCTb040230042Sato Yoshiaki3
已完成
不适用
A clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of LEO 153339 in healthy subjectsPsoriasisNL-OMON51974eo Pharma A/S134
招募中
1 期
Exploratory clinical trial to assess safety, tolerability efficacy and pharmacokinetics of CEB-01 PLGA membrane in participants with pancreatic cancerPancreatic carcinomaMedDRA version: 21.0Level: PTClassification code: 10033609Term: Pancreatic carcinoma Class: 100000004864CTIS2024-512742-42-00Cebiotex S.L.21
尚未招募
1 期
A single center clinical study of evaluating the injection of microRNA2911 plasmid in healthy adultsovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003169anjing University
招募中
Unknown
Clinical trial of TRM-270 for patients undergoing pelvic cavity surgery in the field of obstetrics and gynecologyPatients who are scheduled to undergo pelvic cavity surgery in the field of obstetrics and gynecoloJPRN-jRCT2032230476Sawae Juichi30